Target Name: RNF167
NCBI ID: G26001
Review Report on RNF167 Target / Biomarker Content of Review Report on RNF167 Target / Biomarker
RNF167
Other Name(s): E3 ubiquitin-protein ligase RNF167 | ring finger protein 167 | RNF167 variant 1 | RN167_HUMAN | E3 ubiquitin-protein ligase RNF167 (isoform a) | RING105 | DKFZP566H073 | Ring finger protein 167, transcript variant 1 | RING finger protein 167 | LP2254 | RING-type E3 ubiquitin transferase RNF167 | 5730408C10Rik

Unlocking the Potential of RNF167: A Drug Target and Biomarker for Ubiquitin-Protein Ligase Activities

Introduction

Ubiquitin (U) proteins are involved in a variety of cellular processes, including DNA repair, inflammation, and cell signaling. They serve as targets for various enzymes, including the ubiquitin-protein ligase (UPL) family. One of these enzymes, RNF167, has been identified as a potential drug target and biomarker for various diseases. In this article, we will explore the biology of RNF167 and its potential as a drug target and biomarker.

1. Biological background: RNF167 of the Ubiquitin-Protein Ligase (UPL) family

Ubiquitin (U) is a protein that plays an important role in cellular processes. They serve as targets for a variety of enzymes, including those of the UPL family. Among these enzymes, RNF167 is considered a potential drug target (or biomarker).

1. Bioinformatics analysis: RNA binding protein RNF167

RNA-binding proteins are a class of proteins that bind to nucleic acids and participate in gene expression. RNF167 is an RNA-binding protein that plays an important role within cells. Its main function is to bind and activate other proteins, such as histone-modifying enzymes (HATs) and DNA-binding proteins. When modified, these protein modifications can affect gene expression and cell function.

1. Functional exploration: drug target properties of RNF167

RNF167 has great potential as a drug target. First of all, RNF167 is expressed in a variety of tumors, such as lung cancer, liver cancer, breast cancer, etc. Secondly, RNF167 is closely related to survival and treatment response in various cancers. For example, people with higher expression have a higher risk of lung cancer, while people with lower expression have a higher risk of liver cancer. In addition, the expression level of RNF167 is positively correlated with tumor invasion and metastasis capabilities. Therefore, RNF167 has high clinical value in tumor treatment.

1. Biomarker research: tumor biomarker properties of RNF167

The role of RNF167 in tumor diagnosis and treatment is also reflected in its application as a biomarker. At present, studies have shown that RNF167 can be used as a tumor biomarker for certain cancers, such as lung cancer, liver cancer, breast cancer, etc. In addition, the expression level of RNF167 can also reflect the invasion and metastasis ability of tumors, so it has high clinical value.

1. Drug screening: looking for drugs for RNF167

In order to screen out drugs with higher potential, researchers began to study RNA-binding proteins. They found that some drugs can bind to RNF167 and affect its activity. These drugs include inhibitors, modulators and antibodies. Among them, inhibitors can significantly reduce the activity of RNF167, while modulators and antibodies can increase its activity. These drug screening results provide a new idea for searching for RNA-binding protein drugs.

1. Clinical application prospects: the drug target value of RNF167

With the discovery of RNF167 as a drug target, researchers began to explore its clinical application prospects. By studying RNA-binding proteins, researchers have discovered that RNA-binding proteins can be used as drug targets to treat a variety of tumors. These drugs can include inhibitors, modulators and antibodies. These drugs can significantly increase the activity of RNA-binding proteins, thereby improving tumor treatment effects.

in conclusion

As an RNA-binding protein, RNF167 has great potential as a drug target (or biomarker) for the treatment of various tumors. By studying RNA-binding proteins, we can discover new drug targets and provide a new perspective for further studying the role of RNA-binding proteins in tumor treatment.

Protein Name: Ring Finger Protein 167

Functions: E3 ubiquitin-protein ligase that acts as a regulator of the TORC1 signaling pathway (PubMed:35114100, PubMed:33594058). Positively regulates the TORC1 signaling pathway independently of arginine levels: acts by catalyzing 'Lys-29'-polyubiquitination and degradation of CASTOR1, releasing the GATOR2 complex from CASTOR1 (PubMed:33594058). Also negatively regulates the TORC1 signaling pathway in response to leucine deprivation: acts by mediating 'Lys-63'-linked polyubiquitination of SESN2, promoting SESN2-interaction with the GATOR2 complex (PubMed:35114100). Also involved in protein trafficking and localization (PubMed:23129617, PubMed:23353890, PubMed:24387786, PubMed:27808481, PubMed:32409562). Acts as a regulator of synaptic transmission by mediating ubiquitination and degradation of AMPAR receptor GluA2/GRIA2 (PubMed:23129617, PubMed:33650289). Does not catalyze ubiquitination of GluA1/GRIA1 (PubMed:23129617). Also acts as a regulator of the recycling endosome pathway by mediating ubiquitination of VAMP3 (PubMed:23353890). Regulates lysosome positioning by catalyzing ubiquitination and degradation of ARL8B (PubMed:27808481). Plays a role in growth regulation involved in G1/S transition by mediating, possibly by mediating ubiquitination of SLC22A18 (PubMed:16314844). Acts with a limited set of E2 enzymes, such as UBE2D1 and UBE2N (PubMed:33650289)

The "RNF167 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF167 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P